key: cord-1055889-fpkxkg0y authors: DeMarco, Jennifer K.; Severson, Wiliam E.; DeMarco, Daniel R.; Pogue, Gregory; Gabbard, Jon; Palmer, Kenneth E. title: At the Intersection Between SARS-CoV-2, Macrophages and the Adaptive Immune Response: A Key Role for Antibody-Dependent Pathogenesis But Not Enhancement of Infection in COVID-19 date: 2021-02-23 journal: bioRxiv DOI: 10.1101/2021.02.22.432407 sha: e948b083013be5dbce9d4c217b086a3c3c63e385 doc_id: 1055889 cord_uid: fpkxkg0y Since entering the world stage in December of 2019, SARS-CoV-2 has impacted every corner of the globe with over 1.48 million deaths and caused untold economic damage. Infections in humans range from asymptomatic to severe disease associated with dysregulation of the immune system leading to the development of acute respiratory distress syndrome (ARDs). The distinct shift in peripheral monocyte activation and infiltration of these cells into the respiratory tract in ARDs patients suggests severe COVID-19 may largely result from damage to the respiratory epithelia by improperly activated macrophages. Here, we present evidence that dysregulation of the immune response in COVID-19 begins with activation of macrophages by non-neutralizing antibodies and induction of ACE2 expression, rendering these cells susceptible to killing by SARS-CoV-2. Death of macrophages occurs independently of viral replication and leads to the release of inflammatory mediators and modulation of the susceptibility of downstream epithelial cells to SARS-CoV-2. Since entering the world stage in December of 2019, 24 SARS-CoV-2 has impacted every corner of the globe with over 25 1.48 million deaths and caused untold economic damage. 26 Infections in humans range from asymptomatic to severe disease 27 associated with dysregulation of the immune system leading to the 28 2 development of acute respiratory distress syndrome (ARDs). 29 The distinct shift in peripheral monocyte activation and 30 infiltration of these cells into the respiratory tract in ARDs patients 31 suggests severe COVID-19 may largely result from damage to the 32 respiratory epithelia by improperly activated macrophages. Here, 33 we present evidence that dysregulation of the immune response in A novel coronavirus from 452 patients with pneumonia in China COVID-19 pandemic: Insights into structure, function 458 and hACE2 receptor recognition by SARS-CoV-2 Anayaa 464 JM. 2020. Autoinflammatory and autoimmune conditions at 465 23 the crossroad of COVID-19 Pathogenic T cells and inflammatory 469 monocytes incite inflammatory storm in severe COVID-19 470 patients Synergism of TNF-a and 476 IFN-y triggers inflammatory cell death, tissue damage, and 477 mortality in SARS-CoV-2infection and cytokine storm The Role of Cytokines including Interleukin-6 in COVID-19 482 induced Pneumonia and Macrophage Activation Syndrome-483 Like Disease Aberrant pathogenic GM-CSF+T cells 488 and inflammatory CD14+CD16+ monocytes in severe 489 pulmonary syndrome patients of a new coronavirus SARS-CoV-2 induced immune activation 493 and death of monocyte-derived human macrophages and 494 dendritic cells SARS-CoV-2 evades immune detection in alveolar 500 macrophages Role of Monocytes/Macrophages in Covid-19 Contribution of monocytes and macrophages to the local 508 tissue inflammation and cytokine storm in COVID-19: Lessons 509 from SARS and MERs, and potential therapeutic interventions SARS-CoV-2 receptor ACE2 is co-512 expressed with genes related to transmembrane serine 513 proteases, viral entry, immunity and cellular stress Cytokine storm and 516 leukocyte changes in mild versus severe SARS-CoV-2 infection: 517 Review of 3939 COVID-19 patients in China and emerging 518 pathogenesis and therapy concepts Pathological inflammation in 521 patients with COVID-19: a key role for monocytes and 522 macrophages Modeling COVID-19 with human 529 pluriopotent stem cell-derived cells reveals synergistic effects 530 of anti-inflammatory macrophages with ACE2-inhibition 531 against SARS-CoV-2. Res Sq Preprint Severe Acute Respiratory Syndrome 534 SARS-CoV-2): An overview of viral structure 535 and host response Vaccine-induced enhancement of viral 539 infections Dengue Fever, COVID-542 19 (SARS-CoV-2), and Antibody-Dependent Enhancement 543 (ADE): A Perspective Cytokine storm 546 induced by SARS-CoV-2 Immune cell profiling of COVID-551 19 patients in the recovery stage by single-cell sequencing Tocilizumab for severe COVID-19: a systematic review 556 and meta-analysis Novel coronavirus disease 560 (COVID-19) pandemic: A recent mini review Pragmatic recommendations for 565 therapeutics of hospitalized COVID-19 patients in low-and 566 middle-income countries The 569 use of convalescent plasma for pediatric patients with SARS-570 CoV-2: A systematic literature review REGN-CoV2, a neutralizing antibody 579 cocktail, in outpatients with COVID-19 Development of CpG-adjuvanted stable 584 prefusion SARS-COV-2 spike antigen as a subunit vaccine 585 against COVID-19 2 candidate vaccines: 588 Expectations from Phase III trials and recommendations post-589 1a suggesting that at least two distinct pathways are activated in 632 response to infection with SARS-CoV-2 in macrophages 633 (MP+Ab±Virus) IL-638 2, IP-10, IL-4, IL-9 and IL-17a were observed to be modulated 639 only after infection of macrophages with SARS-CoV-2, suggesting 640 that there are at least two separate pathways (Fc-dependent and Fc-641 independent) through which SARS-CoV-2 initiates production of 642 cytokines in macrophages. Induction of IL-10 was only observed 643 in LPS-activated macrophages suggesting that either macrophages 644 are ARDs patients or that secondary activation of macrophages 646 through Toll-like receptors may play a role during the later stages 647 of the disease Presentation Statement: Preliminary data from this article was 650 presented at IDWeek 2020 (Open Forum Infectious Diseases S319 All correspondence should be directed to